JAAHA Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, P. D.
Right arrow Articles by Losonsky, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, P. D.
Right arrow Articles by Losonsky, J. M.
Journal of the American Animal Hospital Association 39:463-467 (2003)
© 2003 American Animal Hospital Association

Original Article

Gemcitabine as a Radiosensitizer for Nonresectable Feline Oral Squamous Cell Carcinoma

Pamela D. Jones, DVM, Louis-Philippe de Lorimier, DVM, Barbara E. Kitchell, DVM, PhD, Diplomate ACVIM (Internal Medicine Oncology) and John M. Losonsky, DVM, MS, Diplomate ACVR

From the Department of Veterinary Clinical Medicine, Veterinary Teaching Hospital, University of Illinois, 1008 West Hazelwood Drive, Urbana, Illinois 61802.

Eight cats with locally advanced, oral squamous cell carcinoma (SCC) were treated with a combination of gemcitabine and palliative radiotherapy. Low-dose gemcitabine was administered twice weekly (25 mg/m2) in conjunction with megavoltage radiation in 6 Gray (Gy) fractions for a total dose of 36 Gy. Responses included two complete and four partial responses, and two cats had no response to therapy. Median duration of remission was 42.5 days (range, 11 to 85 days). Median survival time was 111.5 days (range, 11 to 234 days). This data suggests that a combination of low-dose gemcitabine and palliative radiation therapy may be tolerable for cats with oral SCC and may cause a therapeutic benefit.




This article has been cited by other articles:


Home page
 Journal of the American Animal Hospital AssociationHome page
M. C. McEntee
Veterinary Radiation Therapy: Review and Current State of the Art
J. Am. Anim. Hosp. Assoc., March 1, 2006; 42(2): 94 - 109.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. K. Park, Y. M. Chung, B.-G. Kim, Y.-A Yoo, B.-S. Yang, J. S. Kim, and Y. D. Yoo
N'-(phenyl-pyridin-2-yl-methylene)-hydrazine carbodithioic acid methyl ester enhances radiation-induced cell death by targeting Bcl-2 against human lung carcinoma cells
Mol. Cancer Ther., April 1, 2004; 3(4): 403 - 407.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Animal Hospital Association.